Defendant
1 case as defendant.
Hikma Pharmaceuticals International Ltd. is an entity within the Hikma group, whose listed parent is Hikma Pharmaceuticals PLC (LSE: HIK; NASDAQ Dubai: HIK; OTC: HKMPY), a FTSE 250 constituent. The group was founded in 1978 in Amman, Jordan, by Samih Darwazah, and is headquartered in London. It is publicly traded; company factsheets and third-party data put FY2025 revenue at roughly $3.3–3.4bn (FY2024 core revenue $3.16bn), with about 9,500–10,600 employees and 29–30 manufacturing plants. I could not independently verify the specific corporate role of the "International Ltd." entity named in the case data; it appears to be a group subsidiary/affiliate.
Operations. Hikma is a multinational generic and specialty pharmaceutical manufacturer operating three segments. Injectables (roughly 42% of revenue) supplies hospitals in North America, Europe and MENA with generic and specialty sterile injectables — vials, bags and prefilled syringes — and is described by the company as a top-three US generic injectable manufacturer by volume. Branded (roughly 24–27%) sells branded generics and in-licensed products to pharmacies and hospitals across MENA. Hikma Rx/Generics (roughly 31–33%) supplies oral solids and liquids, respiratory products and nasal-spray generics to the US retail market, including from its Columbus, Ohio facility. The group reports 800+ products and 13 FDA-inspected plants.
Litigation posture. Operating company, not an NPE. The case data show 0 plaintiff appearances and 1 defendant appearance — consistent with a product manufacturer defending infringement claims rather than asserting patents. The single tracked venue is the District of New Jersey, a common forum for Hatch-Waxman litigation against New Jersey-based brand manufacturers.
Notable case. Celgene Corp. v. Hikma Pharmaceuticals International Ltd. (D.N.J., No. 2:18-cv-13477, filed 2018-08-31; terminated 2019-09-18). Celgene asserted patents including U.S. 6,315,720, 6,561,977, 7,959,566 and 8,315,886 — REMS/distribution and method-of-use patents tied to its Revlimid/Thalomid franchise — against Hikma's proposed generic.
Celgene sued Hikma Pharmaceuticals International over generic lenalidomide; the asserted patents included the '784 patent and eight other patents. The case was terminated on 2019-09-18.